S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Cellectar Biosciences Stock Price, News & Analysis (NASDAQ:CLRB)

$2.47
+0.23 (+10.27%)
(As of 11/30/2023 ET)
Compare
Today's Range
$2.21
$2.54
50-Day Range
$1.94
$2.91
52-Week Range
$1.25
$3.15
Volume
345,230 shs
Average Volume
233,568 shs
Market Capitalization
$30.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Cellectar Biosciences MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
304.9% Upside
$10.00 Price Target
Short Interest
Healthy
6.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Cellectar Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.85) to ($2.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.48 out of 5 stars

Medical Sector

888th out of 949 stocks

Pharmaceutical Preparations Industry

414th out of 435 stocks


CLRB stock logo

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Stock Price History

CLRB Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
CLRB - Cellectar Biosciences, Inc.
Cellectar Biosciences GAAP EPS of -$0.76
See More Headlines
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2021
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLRB
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+306.5%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-28,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.20) per share

Miscellaneous

Free Float
11,723,000
Market Cap
$30.23 million
Optionable
Not Optionable
Beta
1.12
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. James V. Caruso (Age 64)
    President, CEO & Director
    Comp: $846.48k
  • Mr. Chad J. Kolean CPA (Age 59)
    VP, CFO & Secretary
    Comp: $453.22k
  • Mr. Jarrod Longcor (Age 50)
    Chief Operating Officer
    Comp: $625.32k
  • Mr. Darrell Shane Lea (Age 50)
    Chief Commercial Officer
  • Dr. Andrei Shustov M.D. (Age 52)
    Senior Vice President of Medical














CLRB Stock Analysis - Frequently Asked Questions

What is Cellectar Biosciences' stock price target for 2024?

0 Wall Street research analysts have issued twelve-month target prices for Cellectar Biosciences' stock. Their CLRB share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 304.9% from the stock's current price.
View analysts price targets for CLRB
or view top-rated stocks among Wall Street analysts.

How have CLRB shares performed in 2023?

Cellectar Biosciences' stock was trading at $1.71 on January 1st, 2023. Since then, CLRB shares have increased by 44.4% and is now trading at $2.47.
View the best growth stocks for 2023 here
.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a drop in short interest in November. As of November 15th, there was short interest totaling 800,100 shares, a drop of 7.2% from the October 31st total of 861,800 shares. Based on an average trading volume of 708,100 shares, the short-interest ratio is currently 1.1 days. Approximately 6.9% of the company's stock are short sold.
View Cellectar Biosciences' Short Interest
.

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our CLRB earnings forecast
.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its quarterly earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences shares reverse split on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (6.82%), Worth Venture Partners LLC (2.81%) and Acuta Capital Partners LLC (1.22%). Insiders that own company stock include Dov Elefant, James V Caruso and Jarrod Longcor.
View institutional ownership trends
.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLRB) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -